Rusfertide acetate is a Peptide owned by Protagonist Therapeutics, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.

PTG-300 is hepcidin agonist. Hepcidin is a natural peptide hormone that regulates iron homeostasis. Deficiency of this hormone leads to the disease conditions like beta-thalassemia and juvenile hemochromatosis. Hepcidin directly binds to ferroportin and decreases its functional activity by causing it to be internalized from the cell surface and degraded. The drug candiadate by acting as an agonist of hepcidin regulates the downstream iron metabolism.

The revenue for Rusfertide acetate is expected to reach a total of $7.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rusfertide acetate NPV Report.

Rusfertide acetate is originated and owned by Protagonist Therapeutics.

Rusfertide acetate Overview

PTG-300 is under development for the treatment of iron overload related indications including polycythemia vera and hereditary hemochromatosis. It is a hepcidin mimetic. It is injected through subcutaneous route. The drug candidate is developed based on VectrixTM technology platform.

It was also under development for beta-thalassemia and myelodysplastic syndromes.

Protagonist Therapeutics Overview

Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

The company reported revenues of (US Dollars) US$27.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 4.4% over FY2020. The operating loss of the company was US$125.8 million in FY2021, compared to an operating loss of US$65.1 million in FY2020. The net loss of the company was US$125.6 million in FY2021, compared to a net loss of US$66.2 million in FY2020.

Quick View – Rusfertide acetate

Report Segments
  • Innovator
Drug Name
  • Rusfertide acetate
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
  • Hematological Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.